This is a great thread, thanks D and Worth.
The way I read the GSK reference, ATC is miles ahead...
Phase III vs Phase II proof of concept, 100+ vs 32 pts, clinical performance better, etc. Yet IDX899 has scored a deal - upfront payment of USD34m with more later - that sounds fantastic to suffering holders of AVX.
Could this mean Avexa is holding out for some super-deal?
Any thoughts?
CG
Add to My Watchlist
What is My Watchlist?